Stock Events

Stock Events

Fulcrum Therapeutics 

$3.85
41
+$0.01+0.26% Friday 20:00
+$0.00+0%Friday 23:30After hours

Statistics

Day High
3.85
Day Low
3.84
52W High
15.74
52W Low
2.83
Volume
27,748
Avg. Volume
-
Mkt Cap
293.74M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29OctExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.31
-0.25
-0.18
-0.12
Expected EPS
-0.117233
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-74.88MNet Income

Analyst Ratings

3.25Average Price Target
The highest estimate is 4.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
60%
Sell
40%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow FULC. It's not an investment recommendation.
Amazon
7
AMZN
Meta Platforms
7
META
Palantir Technologies
7
PLTR
Microsoft
6
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals is a competitor due to its focus on developing treatments for cystic fibrosis and other serious diseases, overlapping with Fulcrum's focus on rare genetic disorders.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is involved in gene editing technologies, specifically CRISPR/Cas9, which competes with Fulcrum's efforts in developing genetic treatments.
Novartis
NVS
Mkt Cap292.35B
Novartis is a large pharmaceutical company with a broad portfolio that includes treatments for genetic disorders, directly competing with Fulcrum's niche.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical specializes in enzyme replacement therapies for rare genetic disorders, making it a competitor in the rare disease space.
PTC Therapeutics
PTCT
Mkt Cap5.85B
PTC Therapeutics operates in the rare diseases sector, focusing on genetic disorders, which puts it in competition with Fulcrum Therapeutics.
Sarepta Therapeutics
SRPT
Mkt Cap2.2B
Sarepta Therapeutics is known for its work on RNA-targeted therapeutics and gene therapies for rare neuromuscular diseases, competing with Fulcrum's focus areas.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals is a leader in RNAi (RNA interference) therapeutics for genetic diseases, competing with Fulcrum's genetic disorder treatments.
Ultragenyx Pharmaceutical
RARE
Mkt Cap2.52B
Ultragenyx Pharmaceutical focuses on developing products for rare and ultra-rare diseases, including genetic disorders, making it a competitor to Fulcrum.

About

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
Show more...
CEO
Alexander C. Sapir
Employees
55
Country
United States
ISIN
US3596161097

Listings

XNAS
US
FULC
BOATS
BOATS
FULC.BOATS

0 Comments

Share your thoughts

FAQ

What is Fulcrum Therapeutics stock price today?▼
The current price of FULC is $3.85 USD — it has increased by +0.26% in the past 24 hours. Watch Fulcrum Therapeutics stock price performance more closely on the chart.
What is Fulcrum Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Fulcrum Therapeutics stocks are traded under the ticker FULC.
Is Fulcrum Therapeutics stock price growing?▼
FULC stock has risen by +0% compared to the previous week, the month change is a +2.12% rise, over the last year Fulcrum Therapeutics has showed a -49.74% decrease.
What is Fulcrum Therapeutics market cap?▼
Today Fulcrum Therapeutics has the market capitalization of 293.74M
When is the next Fulcrum Therapeutics earnings date?▼
Fulcrum Therapeutics is going to release the next earnings report on October 29, 2026.
What were Fulcrum Therapeutics earnings last quarter?▼
FULC earnings for the last quarter are -0.27 USD per share, whereas the estimation was -0.26 USD resulting in a -5.2% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Fulcrum Therapeutics revenue for the last year?▼
Fulcrum Therapeutics revenue for the last year amounts to 0 USD.
What is Fulcrum Therapeutics net income for the last year?▼
FULC net income for the last year is -74.88M USD.
How many employees does Fulcrum Therapeutics have?▼
As of September 05, 2026, the company has 55 employees.
In which sector is Fulcrum Therapeutics located?▼
Fulcrum Therapeutics operates in the Health & Wellness sector.
When did Fulcrum Therapeutics complete a stock split?▼
Fulcrum Therapeutics has not had any recent stock splits.
Where is Fulcrum Therapeutics headquartered?▼
Fulcrum Therapeutics is headquartered in CAMBRIDGE, United States.